Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:alsoKnownAs |
gptkb:sofosbuvir
|
| gptkbp:approvedBy |
gptkb:FDA
2013 |
| gptkbp:ATCCode |
gptkb:J05AX15
|
| gptkbp:bioavailability |
high
|
| gptkbp:CASNumber |
1190307-88-0
|
| gptkbp:chemicalFormula |
C22H29FN3O9P
|
| gptkbp:combinationTherapy |
ribavirin
ledipasvir velpatasvir |
| gptkbp:developedBy |
gptkb:Gilead_Sciences
|
| gptkbp:discoveredBy |
gptkb:Pharmasset
|
| gptkbp:eliminationHalfLife |
0.4 hours (sofosbuvir), 27 hours (GS-331007 metabolite)
|
| https://www.w3.org/2000/01/rdf-schema#label |
GS-7977
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Sovaldi
|
| gptkbp:mechanismOfAction |
gptkb:NS5B_polymerase_inhibitor
|
| gptkbp:metabolism |
gptkb:GS-331007
|
| gptkbp:patent |
gptkb:Gilead_Sciences
|
| gptkbp:pregnancyCategory |
B1 (Australia)
N (US) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sells |
gptkb:Gilead_Sciences
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue headache insomnia |
| gptkbp:usedFor |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:DB09223
|
| gptkbp:bfsLayer |
5
|